Home > News > Progression Under the Microscope – Can Basic Science Provide the Link Between Structural and Functional Deterioration?
Glaucoma
Read Time: 7 mins

Progression Under the Microscope – Can Basic Science Provide the Link Between Structural and Functional Deterioration?

Published Online: February 2nd 2011 European Ophthalmic Review, 2009,3(2):27-9 DOI: http://doi.org/10.17925/EOR.2009.03.02.27
Authors: Keith R Martin
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

The mechanisms of progression in glaucoma remain incompletely understood, but basic science research is gradually elucidating the processes involved. Axonal injury is a major event in glaucoma and the cellular mechanisms involved in axonal degeneration are different from those that lead to retinal ganglion cell body death. Thus, preventing cell body death is necessary but not sufficient to prevent progressive loss of function in glaucoma, and axonal protection is an important therapeutic goal. Basic science approaches are also suggesting new ways to detect and monitor progression. Techniques to image individual retinal ganglion cells and their axons in the living eye are improving rapidly. Cells undergoing apoptosis can be labelled and identified, and it may be possible in the future to use retinal ganglion cell apoptosis rates as a biomarker of glaucoma progression. However, slow progression may be difficult to detect using such techniques; therefore, biomarkers that identify ganglion cells that are sick but not yet committed to die are an important research goal.

Keywords

Glaucoma, neuroprotection, apoptosis, high-resolution imaging, Wallerian degeneration, axoprotection

Article:

Mechanisms of Progression in Glaucoma Glaucoma is a neurodegenerative disease characterised by progressive loss of retinal ganglion cells (RGCs) over time with associated progressive visual field loss. Elevated intraocular pressure is the strongest risk factor for glaucoma,1 but the mechanisms by which damage occurs in the disease remain incompletely understood; however, a number of important principles have been established. First, there is strong evidence that the optic nerve head is an important site of injury. Characteristic optic nerve changes are observed in glaucoma and correlate with the pattern of visual field loss. Glaucomatous visual field defects often pertain to the horizontal mid-line and such a pattern would be difficult to explain if the site of injury were predominantly to the RGC bodies in the retina. The arcuate nature of many field defects observed in glaucoma also suggests the optic nerve head as the site of injury. In addition to such clinical evidence, recent basic science studies have pointed to the lamina cribrosa region of the optic nerve as a major site of injury in the disease.

Groundbreaking work by Howell et al. using mice with hereditary chronic glaucoma (the DBA/2J strain) provided experimental evidence for a focal insult to optic nerve axons at the glial lamina, the rodent analogue of the lamina cribrosa.2 Damaged axons at the glial lamina appeared dystrophic compared with other portions of the optic nerve in the early stages of DBA/2J glaucoma. The exact nature of the insult experienced by RGC axons at the optic nerve head is unclear, but oxidative stress,3 mitochondrial dysfunction4,5 and failure of glutamate homeostasis6 have all been implicated; other mechanisms are also likely to be involved.

However, although there is strong evidence that the optic nerve head is an important site of injury in glaucoma, this does not preclude the possibility that glaucomatous neurodegeneration may be compounded by factors affecting other RGC compartments. Numerous other mechanisms can potentially affect RGC survival, including toxic and ischaemic injuries at the level of the retina and secondary degeneration, where RGCs not directly injured degenerate later as a consequence of neighbouring cell death.7 Thus, progression in glaucoma is likely to involve a complex interaction between RGC injury at multiple locations, with the optic nerve head probably most significant; the individual’s susceptibility and compensatory responses to glaucomatous stress are also important.

Protecting All Compartments of Retinal Ganglion Cells Is Essential to Prevent Progression
In order to preserve function in glaucoma, it is necessary – but not sufficient – to keep RGC bodies alive in the retina. Maintenance of visual function requires preservation of all compartments of the RGC including the axon, dendrites and distal synapses.8 Only if all components of the cell survive and continue to function can vision be preserved. However, it is becoming clear that the therapeutic strategies required to protect different compartments may differ. As an example, RGC bodies in the retina are known to die by apoptosis,9 which is an active cell death programme that involves a cascade of events that lead to the orderly demise of a cell. In transgenic mice with hereditary glaucoma that also lack Bax, a major component of the apoptotic pathway, RGC loss from the retina is greatly reduced, but axonal degeneration continues.10 Thus, blocking apoptosis is insufficient to prevent RGC axonal degeneration in glaucoma, and therapeutic strategies to protect axons are potentially worth exploring for their ability to alleviate glaucoma progression.

Axoprotection
In order to protect axons it is necessary to understand the mechanisms by which they degenerate. Axonal degeneration can occur by several mechanisms, but Wallerian degeneration frequently occurs, especially following major axonal injury. Wallerian degeneration is an active process that leads to the orderly breakdown of axons in response to injury, and mutations that block this process can enhance axonal survival. The best characterised example mutation that reduces Wallerian degeneration is the slow Wallerian degeneration mutation (WldS). WldS arose spontaneously in mice, where it delayed injury-induced degeneration of distal axon stumps by several weeks in both the peripheral and central nervous system.11 No other mutation is known to protect axons so robustly from Wallerian degeneration, and several studies have demonstrated that WldS protein expression delays axonal degeneration in experimental glaucoma.2,12 We found that WldS delayed axonal degeneration in experimental rat glaucoma for at least two weeks. The duration of axonal protection was similar to that after optic nerve transection and crush, providing further evidence that axonal degeneration in glaucoma follows a Wallerian-like mechanism.12 Axonal degeneration must be prevented to maintain RGC function; therefore, pharmacologically mimicking and enhancing the protective mechanism of WldS could offer an important routetowards therapy. However, WldS did not protect RGC bodies in glaucoma or after other types of optic nerve injury, suggesting that combined treatments to protect both axons and cell bodies may offer the best therapeutic prospects.

Although Wallerian degeneration is the end result of severe axonal injury, lesser insults can also have an effect on axonal function. As an example, axonal transport blockade occurs soon after elevation of intraocular pressure in glaucoma models.13,14 Axonal transport is essential for normal RGC function and is mediated by motor proteins, such as dynein and kinesin, which convey cargo along the microtubules of the axonal cytoskeleton. RGC retrograde transport of brain-derived neurotrophic factor (BDNF) is interrupted by elevated eye pressure, leading to the accumulation of BDNF and its receptor, trkB, at the optic nerve head.14 Impaired delivery of BDNF to the RGC bodies is likely to adversely affect RGC survival, and supplementation of BDNF to the retina, for example by gene therapy, has been shown to mitigate the effect of glaucomatous transport blockade in animal models.15 Other approaches to reduce the effects of axonal transport dysfunction in glaucoma are worth further exploration.

Problems with Detecting Progression in Glaucoma
In addition to helping us understand the mechanisms underlying degeneration of RGC in glaucoma, basic science research is playing an important role in the search for new ways to measure progression. Accurate determination of the presence and rate of progression is essential to the management of glaucoma patients, and is also crucial in the quest to develop new therapies for the disease. However, existing methods to measure progression have significant limitations. Visual field analysis is widely used and is arguably the most clinically relevant measure of glaucoma change as visual function is measured directly. However, most visual field analysis relies on psychophysical testing and as a result variability is a major difficulty. Variability in visual field testing means that multiple tests are often required to confirm progression; therefore, it can take a considerable period of time to confirm whether a patient is deteriorating. This has implications not just for the treatment of individual patients, but also for clinical studies of new potentially neuroprotective treatments where the ‘noisiness’ of visual field end-points contributes to the need for long, and therefore expensive, clinical trials with large numbers of patients.

In addition, visual field changes tend to lag behind RGC loss, with defects developing only after 25–35% of RGCs have been lost at a given retinal location.16 Testing strategies can be modified to improve progression detection using visual field testing, for example by optimising the inter-test interval17 and establishing a rate of progression.18 However, visual fields remain a relatively insensitive measure of glaucoma progression, at least in early disease.

Other approaches to the measurement of progression in current clinical use include assessment of the nerve fibre layer and the 3D structure of the optic nerve head using scanning laser ophthalmoscopy, ocular coherence tomography and polarimetry.19 These techniques can provide evidence of structural changes associated with glaucoma progression, but are relatively insensitive to small changes. Thus, new techniques with the ability to rapidly determine with precision the exact rate of glaucomatous progression would be a major advance.

Using Basic Science to Improve Detection of Progression
Detailed understanding of the mechanisms of RGC loss in glaucoma has the potential to suggest new approaches to the assessment of progression. As an example, the observation that RGC death in glaucoma occurs by apoptosis means that existing techniques to visualise apoptosing cells may be applied to the glaucomatous eye. Technology to image individual RGCs in the living eye and to trace the fate of individual labelled retinal cells over time has advanced rapidly over the last few years.20–22 Cordeiro et al. used annexin V labelling and carefully refined imaging techniques to identify apoptosing retinal cells in the living eye.23 Annexin V specifically labels cells with surface membrane changes characteristic of apoptosis. This technology has also been applied to glaucoma models,24 and a clinical trial in glaucoma patients is also planned. Such techniques represent a potentially important breakthrough in the assessment of glaucomatous progression by allowing individual dying RGCs to be visualised. However, the ability of apoptosis imaging to separate normal RGC attrition due to ageing from glaucomatous progression remains to be established. Given that apoptosing cells can only be detected by annexin V for four to six hours, it is likely that the eye of a slowly progressing glaucoma patient will have a relatively small number of apoptosing cells detectable at a given point in time. Additional challenges will be introduced if the apoptosis rate in glaucoma subjects and controls is not uniform, with cell death occurring in bursts distributed in time and retinal location. High variability in apoptotic rate between individuals will require a greater number of images to determine the average rate of deterioration. It is also conceivable that other tests, such as visual field and nerve fibre layer analysis, could be used to target areas of the retina deemed ‘at risk’ of progression for apoptosis imaging. Such questions can only be answered fully in human glaucoma and thus the results of human trials are awaited with great interest, assuming the technique is found to be safe and effective.

One limitation of apoptosis imaging is the relatively small number of cells likely to be undergoing apoptosis at any given time when glaucoma progression is slow. An alternative approach would be to identify sick RGCs that are not yet committed to die. The rationale for this approach is that there may be a larger population of sick cells evident for much longer than the end stage of apoptosis. The challenge here is to identify detectable markers of sick RGCs. To this end, there are several possible approaches that are showing promise. As discussed earlier, axonal transport dysfunction is a major early event in glaucoma. Techniques now exist to visualise axonal transport in living axons, for example by imaging the movement of mitochondria in transgenic animals where these organelles are fluorescently labelled.25 The combination of such techniques with high-resolution in vivo imaging of the eye could theoretically allow axonal transport to be assessed as a marker of RGC health.
Other possible approaches include searching for characteristic optical ‘signatures’ of sick RGCs using techniques such as ocular coherence tomography (James Morgan, unpublished data). In transgenic animal models that possess small numbers of fluorescent retinal neurons, it is also possible to track the effect of injuries such as glaucoma on the dendritic tree of individual RGCs.22 Although some of these techniques are not likely to be useful in humans, the principle of detecting sick cells may be as useful as detecting those committed to die, and is worthy of further exploration.

Summary
Basic science approaches are the key to understanding the links between RGC injury in glaucoma and the resultant structural and functional deterioration that occurs as the disease progresses. Understanding the basic mechanisms of RGC degeneration can not only facilitate the identification of new therapeutic targets, but also suggest new ways in which progression can be detected and quantified. Moreover, basic science is essential for the ultimate goal of rapidly identifying progressing patients for their inclusion in shorter, more affordable clinical trials of novel potential neuroprotective therapies.

Article Information:
Disclosure

Keith R Martin is supported by a GlaxoSmithKline (GSK) Clinician Scientist Fellowship, a Fight for Sight (UK) research grant and the Glaucoma Foundation.

Correspondence

Keith R Martin, Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UK. E: krgm2@cam.ac.uk

Support

Supported by Pfizer. The views expressed are those of the authors and not necessarily those of Pfizer.

Received

2009-09-01T00:00:00

References

  1. Kass MA, Heuer DK, Higginbotham EJ, et al., The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma, Arch Ophthalmol, 2002;120(6):701–13, discussion 829–30.
  2. Howell GR, Libby RT, Jakobs TC, et al., Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma, J Cell Biol, 2007;179(7):1523–37.
  3. Tezel G, Wax MB, Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells, J Neurosci, 2000;20(23): 8693–8700.
  4. Ju WK, Kim KY, Lindsey JD, et al., Intraocular pressure elevation induces mitochondrial fission and triggers OPA1 release in glaucomatous optic nerve, Invest Ophthalmol Vis Sci, 2008;49(11):4903–11.
  5. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG, Mitochondrial dysfunction and glaucoma, J Glaucoma, 2009;18(2):93–100.
  6. Martin KR, Levkovitch-Verbin H, Valenta D, et al., Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat, Invest Ophthalmol Vis Sci, 2002;43(7):2236–43.
  7. Levkovitch-Verbin H, Quigley HA, Martin KR, et al., A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection, Invest Ophthalmol Vis Sci, 2003;44(8):3388–93.
  8. Whitmore AV, Libby RT, John SW, Glaucoma: thinking in new ways – a role for autonomous axonal self-destruction and other compartmentalised processes?, Prog Retin Eye Res, 2005;24(6):639–62.
  9. Quigley HA, Nickells RW, Kerrigan LA, et al., Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis, Invest Ophthalmol Vis Sci, 1995;36(5):774–86.
  10. Libby RT, Li Y, Savinova OV, et al., Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage, PLoS Genet, 2005;1(1):17–26.
  11. Perry VH, Brown MC, Lunn ER, Very Slow Retrograde and Wallerian Degeneration in the CNS of C57BL/Ola Mice, Eur J Neurosci, 1991;3(1):102–5.
  12. Beirowski B, Babetto E, Coleman MP, Martin KR, The WldS gene delays axonal but not somatic degeneration in a rat glaucoma model, Eur J Neurosci, 2008;28(6):1166–79.
  13. Martin KR, Quigley HA, Valenta D, et al., Optic nerve dynein motor protein distribution changes with intraocular pressure elevation in a rat model of glaucoma, Exp Eye Res, 2006;83(2):255–62.
  14. Pease ME, McKinnon SJ, Quigley HA, et al., Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma, Invest Ophthalmol Vis Sci, 2000;41(3):764–74.
  15. Martin KR, Quigley HA, Zack DJ, et al., Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model, Invest Ophthalmol Vis Sci, 2003;44(10):4357–65.
  16. Kerrigan-Baumrind LA, Quigley HA, Pease ME, et al., Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons, Invest Ophthalmol Vis Sci, 2000;41(3):741–8.
  17. Chauhan BC, Garway-Heath DF, Goni FJ, et al., Practical recommendations for measuring rates of visual field change in glaucoma, Br J Ophthalmol, 2008;92(4):569–73.
  18. Viswanathan AC, Crabb DP, McNaught AI, et al., Interobserver agreement on visual field progression in glaucoma: a comparison of methods, Br J Ophthalmol, 2003;87(6):726–30.
  19. Medeiros FA, Zangwill LM, Bowd C, Weinreb RN, Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma, Arch Ophthalmol, 2004;122(6): 827–37.
  20. Leung CK, Lindsey JD, Crowston JG, et al., Longitudinal profile of retinal ganglion cell damage after optic nerve crush with blue-light confocal scanning laserophthalmoscopy, Invest Ophthalmol Vis Sci, 2008; 49(11): 4898–4902.
  21. Murata H, Aihara M, Chen YN, et al., Imaging mouse retinal ganglion cells and their loss in vivo by a fundus camera in the normal and ischemia-reperfusion model, Invest Ophthalmol Vis Sci, 2008;49(12):5546–52.
  22. Walsh MK, Quigley HA, In vivo time-lapse fluorescence imaging of individual retinal ganglion cells in mice, J Neurosci Methods, 2008;169(1):214–21.
  23. Cordeiro MF, Guo L, Luong V, et al., Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration, Proc Natl Acad Sci U S A, 2004;101(36):13352–6.
  24. Guo L, Cordeiro MF, Assessment of neuroprotection in the retina with DARC, Prog Brain Res, 2008;173:437–50.
  25. Misgeld T, Kerschensteiner M, Bareyre FM, et al., Imaging axonal transport of mitochondria in vivo, Nat Methods, 2007;4(7):559–61.

Further Resources

Share this Article
Related Content In Glaucoma
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72